Litcius/Paper detail

Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010–02)

S. Racadot, Isabelle Thennevet, Yaëlle Ouldbey, Marie‐Christine Kaminsky, M. Bosset, Laurent Martin, Yungan Tao, Christian Sire, D. De Raucourt, M. Alfonsi, Emmanuelle Malaurie, Jean‐Marc Tourani, P. Fournel, Élodie Vauléon, A. Modesto, Frédéric Rolland, Séverine Metzger, P. Pommier, Sylvie Chabaud, Sophie Dussart

2022European Journal of Cancer11 citationsDOI

Topics & Concepts

AfatinibMedicinePlaceboClinical endpointSurgeryInternal medicineHead and neck squamous-cell carcinomaDiscontinuationRadiation therapyRandomized controlled trialHead and neck cancerOncologyCancerErlotinibPathologyAlternative medicineEpidermal growth factor receptorHead and Neck Cancer StudiesFibroblast Growth Factor ResearchLung Cancer Treatments and Mutations
Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010–02) | Litcius